← Back to Search

Messaging informed by construal level theory for Coronavirus

N/A
Waitlist Available
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2-5 days
Awards & highlights

Study Summary

This trial will test different messages to see which one is most effective in getting people to get the COVID booster vaccine. The primary outcome is the rate of booster vaccination at the targeted visit, and the secondary outcome is the rate of receipt of a COVID booster vaccine within 6 weeks of the targeted visit.

Eligible Conditions
  • Coronavirus
  • Vaccine Refusal

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2-5 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2-5 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants Who Received a Booster Vaccination Through the Targeted Visit
Secondary outcome measures
Number of Participants Who Received a Booster Vaccination Within 6 Weeks of the Targeted Visit

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: "Why" messagingExperimental Treatment1 Intervention
In this arm, patients will be sent an electronic patient portal message a few days in advance of their office visit. Messages will focus on reasons to get the COVID booster vaccine, including protecting self and loved ones or the idea of herd immunity.
Group II: "How" messagingExperimental Treatment1 Intervention
In this arm, patients will be sent an electronic patient portal message a few days in advance of their office visit. "How" messages will focus on the details of obtaining a vaccination at MGB, what to expect, and how to prepare for the visit.
Group III: Usual CareActive Control1 Intervention
In this arm, patients will not receive any additional message about their upcoming visit, beyond what they already receive by the health system.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Messaging informed by construal level theory
2022
N/A
~3680

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)NIH
1,672 Previous Clinical Trials
28,014,992 Total Patients Enrolled
Brigham and Women's HospitalLead Sponsor
1,614 Previous Clinical Trials
11,467,164 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies for participants in this clinical experiment?

"According to records on clinicaltrials.gov, the trial that was initiated on February 18th 2022 and last updated June 2nd 2022 has stopped enrolling patients. However, 1043 other studies are presently accepting participants for their experiments."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19
Nancy Haff, MD, MPH 2022. "Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04871776.
~1159 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top